- Home
- HL vs RYTM Comparison
HL vs RYTM Comparison
Compare HL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- RYTM
- Stock Information
- Founded
- HL 1891
- RYTM 2008
- Country
- HL United States
- RYTM United States
- Employees
- HL N/A
- RYTM N/A
- Industry
- HL Precious Metals
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HL Basic Materials
- RYTM Health Care
- Exchange
- HL Nasdaq
- RYTM Nasdaq
- Market Cap
- HL 4.1B
- RYTM 3.8B
- IPO Year
- HL N/A
- RYTM 2017
- Fundamental
- Price
- HL $5.81
- RYTM $61.74
- Analyst Decision
- HL Strong Buy
- RYTM Strong Buy
- Analyst Count
- HL 3
- RYTM 12
- Target Price
- HL $8.50
- RYTM $74.92
- AVG Volume (30 Days)
- HL 21.8M
- RYTM 940.6K
- Earning Date
- HL 05-07-2025
- RYTM 05-06-2025
- Dividend Yield
- HL 0.64%
- RYTM N/A
- EPS Growth
- HL N/A
- RYTM N/A
- EPS
- HL 0.06
- RYTM N/A
- Revenue
- HL $929,925,000.00
- RYTM $130,126,000.00
- Revenue This Year
- HL $8.07
- RYTM $43.84
- Revenue Next Year
- HL $3.08
- RYTM $65.62
- P/E Ratio
- HL $102.33
- RYTM N/A
- Revenue Growth
- HL 29.12
- RYTM 68.06
- 52 Week Low
- HL $4.41
- RYTM $35.17
- 52 Week High
- HL $7.68
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HL 55.58
- RYTM 61.94
- Support Level
- HL $4.46
- RYTM $59.54
- Resistance Level
- HL $6.21
- RYTM $62.83
- Average True Range (ATR)
- HL 0.34
- RYTM 4.27
- MACD
- HL 0.07
- RYTM 1.00
- Stochastic Oscillator
- HL 77.14
- RYTM 92.04
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Nevada Operations. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada , United States and Mexico and it derives a majority of its revenue from United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.